South Africa Insulin Drugs And Delivery Devices Market Size
| Study Period | 2018 - 2028 |
| Base Year For Estimation | 2022 |
| Forecast Data Period | 2024 - 2028 |
| Market Size (2024) | USD 191 Million |
| Market Size (2028) | USD 196 Million |
| CAGR (2024 - 2028) | 0.30 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
South Africa Insulin Drugs And Delivery Devices Market Analysis
The South Africa Insulin Drugs and Delivery Devices Market size is estimated at USD 191 million in 2023, and is expected to reach USD 196 million by 2028, growing at a CAGR of 0.3% during the forecast period (2023-2028).
Diabetes mellitus had a considerable impact on COVID-19-affected people and society due to the high costs associated with its care, and the complications that arose from it. Diabetes mellitus imposed a greater risk of extended hospital stay and death. In addition to the direct effects on health, the absence of regular care due to the closure of outpatient clinics and social isolation with changes in diet, physical activity, and personal care favored the deterioration of disease control and hampered the detection of complications. As a result, there was an urgent need to provide an enhanced understanding of self-management, follow-up care, telemedicine, and glycemic management.
There are two main types of diabetes, type 1, and type 2. Type 1 diabetes is an autoimmune disease, in which the body cannot make insulin properly, and is more commonly diagnosed in young people. In type 2 diabetes, the body becomes resistant to the effects of insulin. Diabetes treatment aims to maintain healthy blood glucose levels to prevent both short and long-term complications, such as cardiovascular disease, kidney disease, blindness, and lower limb amputation. For a patient with type 1 diabetes, insulin therapy is important for replacing the insulin which the body doesn't produce. People with type 2 diabetes need insulin therapy if other treatments such as diabetes medications and other lifestyle changes are not able to keep blood glucose levels within the desired range.
A systematic approach to the organization of care is essential for diabetes including well-trained and dedicated personnel, calibrated and functioning equipment, management and referral protocols, regular and sustainable supply of medication, syringes, and consumables, a register of all patients, and annual review charts. Various protocols such as the South Africa Diabetes Declaration Implementation Strategy, Long-term care model Implementation Plan, National Guideline: Non-Communicable Diseases: A Strategic Vision, Chronic Diseases Indicators, and Records with these updated guidelines facilitate improved quality of diabetes care.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
South Africa Insulin Drugs And Delivery Devices Market Trends
Rising diabetes prevalence
In South Africa, Diabetes Population is expected to increase with a CAGR greater than 2.5% over the forecast period.
According to IDF Diabetes Atlas latest estimates, one in nine adults in South Africa is living with diabetes. The diabetes prevalence in South Africa has reached 11.3%, the highest in Africa. The cost of diabetes-related health expenditure has risen to 1,700 USD per person which is estimated to be around 7.2 billion USD. In South Africa, diabetes is the fastest-growing disease, and the country has a high number of diabetic patients. The prevalence of diabetes is growing among all ages in South Africa, which can be attributed to the increasingly obese population, along with an unhealthy diet and a sedentary lifestyle.
One of the most effective ways to decrease the prevalence of diabetes in South Africa is to educate citizens and encourage healthy decision-making. South Africa is currently working towards this goal. One recent preventative measure taken by the South African government is the implementation of a sugar tax. By charging more for sugary drinks and foods, the government is fighting obesity and helping citizens make more conscious decisions. South Africa launched a Diabetes Prevention Programme (DPP). The DPP aims to integrate intervention treatments for at-risk individuals.
Diabetes South Africa, Society for Endocrinology, Metabolism and Diabetes of South Africa, and Youth with Diabetes are the various organizations in South Africa working towards helping diabetes patients. The organizations are promoting the allocation of an increased budget dedicated to funding all aspects of diabetes care and providing a system for better coordination with the Council of Medical Schemes, the organization in charge of reimbursement, to limit out-of-pocket payments and prevent increased expenditure for patients. Pharmacologic therapy such as oral medicines and insulin, as well as non-pharmacologic therapies such as lifestyle changes, are modern approaches for diabetes management. These therapies are only possible through proper blood glucose monitoring and self-care.
The Insulin Syringes Segment is Expected to Witness Highest Growth Rate Over the Forecast Period
The insulin Syringe Segment is expected to grow with a CAGR of more than 3.8% in the market during the forecast period.
Type 1 diabetes is caused due to the inability of the pancreas to produce insulin. Hence, type 1 patients are mostly prescribed with the intake of the hormone. Usually, doctors prescribe type 2 diabetes patients to take Insulin through external sources like an Insulin syringe. The Insulin syringe can be used by any diabetic patient to take Insulin as per the recommendation of a medical expert. However, depending on the type and brand, all types of Insulin cannot be used through an Insulin syringe.
Insulin syringes are more affordable when compared to other methods of administering Insulin such as Insulin pens, etc. Hereby, the wastage of Insulin is also restricted as the units of Insulin needed can be easily read in the barrel of the syringe and only the required amount can be taken out from the Insulin bottle. Prefilled syringes have gained acceptance in the market as drug delivery systems designed for injectable drugs. Prefilled syringes provide the advantage of precise dosing, as the syringes are already loaded with a dose worth of the drug.
Diabetes South Africa is a nonprofit organization that focuses on educating citizens and lobbying the government for better facilities and cheaper healthcare. Further, SEMDSA researches the genetic sources and causes of diabetes. This organization also promotes high standards of treatment and encourages the widespread availability of medicine. The organizations are promoting the allocation of an increased budget dedicated to funding all aspects of diabetes care and providing a system for better coordination with the Council of Medical Schemes, the organization in charge of reimbursement, to limit out-of-pocket payments and prevent increased expenditure for patients.
Such factors are likely to boost the market prospects in the years to come.
South Africa Insulin Drugs And Delivery Devices Industry Overview
The South Africa Insulin Drugs and Delivery Devices Market is semi-consolidated, with few significant and generic players. The major players are working on innovations in insulin drugs and devices which is evident from the companies spending on research and developments to strengthen their market presence.
South Africa Insulin Drugs And Delivery Devices Market Leaders
-
Novo Nordisk
-
Julphar
-
Pfizer
-
Sanofi
-
Novartis
*Disclaimer: Major Players sorted in no particular order
South Africa Insulin Drugs And Delivery Devices Market News
- September 2023: Novo Nordisk announced a new partnership to establish human insulin production in South Africa as part of an expanded commitment to provide life-saving treatment to people living with diabetes across the African continent. Novo Nordisk will work with Aspen SA Operations (Pty) Ltd. and Aspen Pharmacare Holdings Limited (Aspen) in South Africa to step up the existing supply of affordable human insulin.
- May 2023: Medtronic plc announced it has entered into a set of definitive agreements to acquire EOFlow Co. Ltd., manufacturer of the EOPatch device - a tubeless, wearable, and fully disposable insulin delivery device. The addition of EOFlow, together with Medtronic's Meal Detection Technology algorithm and next-generation continuous glucose monitor (CGM), is expected to expand the company's ability to address the needs of more individuals with diabetes.
South Africa Insulin Drugs And Delivery Devices Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.3 Market Restraints
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products and Services
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 Drug
5.1.1 Basal or Long-acting Insulins
5.1.1.1 Lantus (Insulin Glargine)
5.1.1.2 Levemir (Insulin Detemir)
5.1.1.3 Toujeo (Insulin Glargine)
5.1.1.4 Tresiba (Insulin Degludec)
5.1.1.5 Basaglar (Insulin Glargine)
5.1.2 Bolus or Fast-acting Insulins
5.1.2.1 NovoRapid/Novolog (Insulin aspart)
5.1.2.2 Humalog (Insulin lispro)
5.1.2.3 Apidra (Insulin glulisine)
5.1.2.4 FIASP (Insulin aspart)
5.1.2.5 Admelog (Insulin lispro Sanofi)
5.1.3 Traditional Human Insulins
5.1.3.1 Novolin/Mixtard/Actrapid/Insulatard
5.1.3.2 Humulin
5.1.3.3 Insuman
5.1.4 Combination Insulins
5.1.4.1 NovoMix (Biphasic Insulin aspart)
5.1.4.2 Ryzodeg (Insulin degludec and Insulin aspart)
5.1.4.3 Xultophy (Insulin degludec and Liraglutide)
5.1.4.4 Soliqua/Suliqua (Insulin glargine and Lixisenatide)
5.1.5 Biosimilar Insulins
5.1.5.1 Insulin Glargine Biosimilars
5.1.5.2 Human Insulin Biosimilars
5.2 Device
5.2.1 Insulin Pumps
5.2.1.1 Insulin Pump Devices
5.2.1.2 Insulin Pump Reservoirs
5.2.1.3 Insulin Infusion sets
5.2.2 Insulin Pens
5.2.2.1 Cartridges in reusable pens
5.2.2.2 Disposable insulin pens
5.2.3 Insulin Syringes
5.2.4 Insulin Jet Injectors
6. MARKET INDICATORS
6.1 Type-1 Diabetes Population
6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
7.1 COMPANY PROFILES
7.1.1 Novo Nordisk
7.1.2 Sanofi
7.1.3 Eli Lilly
7.1.4 Gan & Lee
7.1.5 Biocon
7.1.6 Julphar
7.1.7 Medtronic
7.1.8 Ypsomed
7.1.9 Becton Dickinson
7.1.10 Pfizer
7.1.11 Novartis
- *List Not Exhaustive
7.2 COMPANY SHARE ANALYSIS
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
South Africa Insulin Drugs And Delivery Devices Industry Segmentation
There are different ways to inject insulin into a patient’s body using syringes, pens, pumps, and jet injectors giving them various options for insulin delivery. The South Africa Insulin Drugs and Delivery Devices Market is segmented into Drugs (Basal or Long-acting Insulins, Bolus or Fast-acting Insulins, Traditional Human Insulins, Combination Insulins, and Biosimilar Insulins) and Devices (Insulin Pens, Insulin Pumps, Insulin Syringes, and Jet Injectors). The report offers the value (in USD) and volume (in Units) for the above segments.
| Drug | |||||||
| |||||||
| |||||||
| |||||||
| |||||||
|
| Device | |||||
| |||||
| |||||
| Insulin Syringes | |||||
| Insulin Jet Injectors |
South Africa Insulin Drugs And Delivery Devices Market Research Faqs
How big is the South Africa Insulin Drugs And Delivery Devices Market?
The South Africa Insulin Drugs And Delivery Devices Market size is expected to reach USD 191 million in 2024 and grow at a CAGR of 0.3% to reach USD 196 million by 2028.
What is the current South Africa Insulin Drugs And Delivery Devices Market size?
In 2024, the South Africa Insulin Drugs And Delivery Devices Market size is expected to reach USD 191 million.
Who are the key players in South Africa Insulin Drugs And Delivery Devices Market?
Novo Nordisk, Julphar, Pfizer, Sanofi and Novartis are the major companies operating in the South Africa Insulin Drugs And Delivery Devices Market.
What years does this South Africa Insulin Drugs And Delivery Devices Market cover, and what was the market size in 2023?
In 2023, the South Africa Insulin Drugs And Delivery Devices Market size was estimated at USD 190.43 million. The report covers the South Africa Insulin Drugs And Delivery Devices Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the South Africa Insulin Drugs And Delivery Devices Market size for years: 2024, 2025, 2026, 2027 and 2028.
South Africa Insulin Drugs And Delivery Devices Industry Report
Statistics for the 2024 South Africa Insulin Drugs And Delivery Devices market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. South Africa Insulin Drugs And Delivery Devices analysis includes a market forecast outlook for 2024 to 2028 and historical overview. Get a sample of this industry analysis as a free report PDF download.
